[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

United Therapeutic (UTHR)

United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,635,336
  • Shares Outstanding, K 42,447
  • Annual Sales, $ 3,183 M
  • Annual Income, $ 1,335 M
  • EBIT $ 1,436 M
  • EBITDA $ 1,521 M
  • 60-Month Beta 0.60
  • Price/Sales 7.50
  • Price/Cash Flow 17.04
  • Price/Book 4.04

Options Overview Details

View History
  • Implied Volatility 32.22% (-0.10%)
  • Historical Volatility 24.53%
  • IV Percentile 12%
  • IV Rank 9.02%
  • IV High 92.62% on 08/25/25
  • IV Low 26.23% on 06/18/25
  • Expected Move (DTE 19) 20.91 (3.76%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 56
  • Volume Avg (30-Day) 1,650
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 25,816
  • Open Int (30-Day) 34,377
  • Expected Range 535.91 to 577.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $6.86
  • Number of Estimates 6
  • High Estimate $7.48
  • Low Estimate $6.07
  • Prior Year $6.41
  • Growth Rate Est. (year over year) +7.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
548.03 +1.60%
on 05/29/26
609.35 -8.62%
on 05/06/26
-14.25 (-2.50%)
since 04/29/26
3-Month
471.29 +18.15%
on 03/06/26
609.35 -8.62%
on 05/06/26
+52.92 (+10.50%)
since 02/27/26
52-Week
272.12 +104.62%
on 07/31/25
609.35 -8.62%
on 05/06/26
+241.18 (+76.41%)
since 05/28/25

Most Recent Stories

More News
2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down

2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down

NVMI : 502.33 (-0.72%)
SYF : 71.44 (-0.04%)
UTHR : 556.82 (-0.94%)
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on...

UTHR : 556.82 (-0.94%)
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026

The pivotal TETON-1 phase 3 study of nebulized Tyvaso® (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis ( IPF ) preserved lung function...

UTHR : 556.82 (-0.94%)
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

The long-term, pivotal, phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag achieving a statistically significant 55% reduction in risk of clinical worsening...

UTHR : 556.82 (-0.94%)
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial

First-ever human clinical trial of a xenoheart intended to support potential registration through the submission of a Biologics License Application to the U.S. FDA

UTHR : 556.82 (-0.94%)
5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call

5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call

UTHR : 556.82 (-0.94%)
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide a company overview and update on...

UTHR : 556.82 (-0.94%)
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

Presentations of results from the positive TETON phase 3 pivotal studies of inhaled treprostinil in idiopathic pulmonary fibrosis ( IPF ) include efficacy and safety results from ...

UTHR : 556.82 (-0.94%)
UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook

UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook

UTHR : 556.82 (-0.94%)
United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings

United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings

UTHR : 556.82 (-0.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by...

See More

Key Turning Points

3rd Resistance Point 578.91
2nd Resistance Point 570.97
1st Resistance Point 563.90
Last Price 556.82
1st Support Level 548.89
2nd Support Level 540.95
3rd Support Level 533.88

See More

52-Week High 609.35
Last Price 556.82
Fibonacci 61.8% 480.53
Fibonacci 50% 440.73
Fibonacci 38.2% 400.94
52-Week Low 272.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.